Dr Lal Pathlabs Ltd Share Price Today - Dr Lal Pathlabs Ltd Live Updates NSE/BSE

NSEBSE

There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.

Max

Open1,835

High1,857.6

Low1,824.1

Prev. Close1,843.7

Avg. Traded Price1,838.09

Volume3,49,768

MARKET DEPTH

Total bid0.00

Total ask22.00

Orders	Qty	Bid
0	0	0
0	0	0
0	0	0
0	0	0
0	0	0

Ask	Qty	Orders
1843.7	2	22
0	0	0
0	0	0
0	0	0
0	0	0

HIGH/LOW

52w

LOW/HIGH

₹1824.1019 hours ago

₹1857.6014 hours ago

LOWER/UPPER CIRCUITS

₹1468.90

₹2203.30

Dr Lal Pathlabs Ltd Stock performance

KEY OBSERVATIONS

positive

negative

neutral

Annual Revenue,rose 12.11%, in the last year to ₹2,864.18 Cr. Its sector's average revenue growth for the last fiscal year was 20.52%.

Annual Net Profit,rose 3.62% in the last year to ₹504.78 Cr. Its sector's average net profit growth for the last fiscal year was -17.16%.

Return on Equity(ROE),for the last financial year was 20.12%, more than 20% in the last financial year, indicating an efficient use of shareholder's capital to generate profit.

LONG-TERM PRICE ANALYSIS

Stock return5Y CAGR : 16.73%

Net profit growth 5Y CAGR : 16.68%

About Dr. Lal PathLabs Limited

Dr. Lal PathLabs Limited is a public company incorporated on February 14 1995. Its registered office at Block E, Sector-18, Rohini, New Delhi 110085 . The company traces its roots to 1949 and today provides a comprehensive menu of 5,000+ diagnostic tests and panels, including specialised and genomic testing, through a nationwide network of laboratories and service centres.

Its portfolio spans biochemistry, haematology, histopathology, microbiology, immunology, virology, cytology, electrophoresis, immuno-chemistry, and radiology investigations, alongside branded offerings such as Genevolve (genomics), L-CoRD (reproductive diagnostics) and L-ACE (autoimmune disorders), plus AI-enabled diagnostics and tech-enabled sample tracking . Dr. Lal PathLabs operates across India with international subsidiaries and labs in Nepal and Bangladesh, reflecting a Pan-India footprint with select overseas presence.

Dr. Lal PathLabs Limited Key Milestones

Key milestones include establishing Asia’s largest National Reference Lab in Delhi (2010), becoming the first Indian healthcare company to list via IPO (2015), launching the first COVID RT-PCR testing network in India’s private sector (2020), and subsequent expansions such as reference labs in Mumbai and Bengaluru and acquisitions like Suburban Diagnostics (2021) .

Dr. Lal PathLabs Limited’s Business Segments

Market segments (FY25 revenue mix): B2C 74%; B2B 26% .
Geography (FY25 mix): International operations contributed less than 2% of total revenue; the balance was domestic .
Within India (FY25 region-wise revenue contribution): Delhi NCR 31.08%; UP & Uttarakhand 18.62%; Rest of North 13.20%; East 14.55%; West 14.62%; South 5.62%; Others 2.31%.

Dr. Lal PathLabs Limited Key Management

(Hony) Brig. Dr. Arvind Lal – Executive Chairman.
Shankha Banerjee – Chief Executive Officer (w.e.f. May 21, 2024) .
Ved Prakash Goel – Chief Financial Officer & CEO – International Business.
Vinay Gujral – Company Secretary & Compliance Officer.

Latest Updates on Dr. Lal PathLabs Limited

Network expansion: In FY25, the company opened 18 new labs and added 800+ collection centres to deepen reach, particularly into Tier 3 and Tier 4 locations, while continuing investments in metro and tiered city infrastructure .
Portfolio enhancement: Nearly 80 high-end tests were added during the year, strengthening specialised and complex testing capabilities; the SwasthFit preventive health packages contributed 24% of sales in FY25 .
Digital and AI: The company continued deploying AI across cancer diagnostics, autoimmunity, antibiotic sensitivity, haematology and other departments, as part of a broader digital transformation strategy covering medical technology, AI & automation, and infra upgrades .
Operating scale: As of FY25, the network comprised 298 labs, 6,607 patient service centres and 12,365 pick-up points, serving 28.8 million patients and processing 85.6 million samples; 40 labs were NABL-accredited and 2 were CAP-accredited .
Corporate actions: Suburban Diagnostics’ business undertaking was consolidated into Dr. Lal PathLabs on a going-concern basis effective March 18, 2025, following a voluntary liquidation process approved in February 2025.

Similar stocks

APOLLOHOSP₹7604.50+4.50 (0.06%)

MANIPALHOS₹625.40-2.15 (0.34%)

MAXHEALTH₹817.00-2.90 (0.35%)

ASTERDM₹654.70+4.55 (0.70%)

FORTIS₹726.65-2.35 (0.32%)

Grow your wealth with more research recommendations

+91

Frequently Asked Questions

What was today's high for Dr Lal Pathlabs Ltd share?

The intraday high for Dr Lal Pathlabs Ltd on the NSE today (22 Oct 2026) was ₹1,857.60. This compares to the 52-week high of ₹2,038.60 recorded on 16 Sep 2026. Today's high was -8.88% below the 52-week high.

How much return has Dr Lal Pathlabs Ltd given in the last 3 months?

Dr Lal Pathlabs Ltd has delivered a return of 8.07% over the last 3 months. The stock was trading at ₹1,699.00 on 22 Jul 2026 and is currently at ₹1,843.70 as of 22 Oct 2026, reflecting a Gain of ₹144.70 per share over this period.

How much return has Dr Lal Pathlabs Ltd given in the last 52 weeks?

Dr Lal Pathlabs Ltd has delivered 19.55% return over the last 52 weeks. During this period, the stock hit a 52-week high of ₹2,038.60 on 16 Sep 2026 and a 52-week low of ₹1,272.60 on 23 Mar 2026. It is currently trading at ₹1,843.70 as of 22 Oct 2026.

What is the highest Dr Lal Pathlabs Ltd share price ever recorded and when?

The all-time high (ATH) for Dr Lal Pathlabs Ltd was ₹2,104.30, recorded on 15 Sep 2021. At the current price of ₹1,843.70, the stock is trading 12.38% below its all-time high. The all-time low recorded was ₹360.18 on 20 Jan 2016.

What is the return of Dr Lal Pathlabs Ltd in the past 5 years?

Dr Lal Pathlabs Ltd has delivered a 8.54% absolute return over the past 5 years, equivalent to a CAGR of 1.65% per annum. The stock was priced at ₹1,698.64 in Oct 2021 and has risen to ₹1,843.70 as of 22 Oct 2026. An investment of ₹1,00,000 in Dr Lal Pathlabs Ltd five years ago would be worth ₹1,08,540.00 today.

Has Dr Lal Pathlabs Ltd offered any dividend in the past 5 years?

Yes,Dr Lal Pathlabs Ltd has declared a consistent dividend every year over the past 5 years. The company paid a total dividend of 91.50 per share between FY2022 and FY2026, with the most recent dividend of ₹5.00 per share for Jul 26, with an ex-dividend date of 30 Jul 2026. At the current market price of ₹1,843.70, the trailing dividend yield of Dr Lal Pathlabs Ltd stands at 25.50%.

What is the share price of Dr Lal Pathlabs Ltd?

As of 22 Oct 2026, the share price of Dr Lal Pathlabs Ltd is ₹1,843.70 on the NSE and ₹1,832.10 on the BSE. The stock opened at ₹1,835.00, touched a high of ₹1,857.60 and a low of ₹1,824.10 during today's session.

How much return has Dr Lal Pathlabs Ltd given in the last 6 months?

Over the last 6 months, Dr Lal Pathlabs Ltd has given a return of 25.84%. The stock was priced at ₹1,459.10 on 22 Apr 2026 and has Rise to ₹1,843.70 as of 22 Oct 2026, a change of ₹384.60 per share.

What was Dr Lal Pathlabs Ltd's low today on the NSE?

The intraday low for Dr Lal Pathlabs Ltd on the NSE today was ₹1,824.10. The stock's 52-week low stands at ₹1,272.60, recorded on 23 Mar 2026. Today's low is 43.34% above the 52-week low, indicating the stock is trading well above its yearly lows.

What were the most recent reported sales and net income of Dr Lal Pathlabs Ltd?

For Q1 FY27, Dr Lal Pathlabs Ltd reported: Revenue (Net Sales): ₹7644.00 Cr - Up 13.21% year-on-year from ₹6752.00 Cr in Q4 FY26. Net Income (PAT): ₹1659.00 Cr - Up 17.58% year-on-year from ₹1411.00 Cr in Q4 FY26.